Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. Stock

Equities

300937

CNE100004CV9

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-09 pm EDT 5-day change 1st Jan Change
23.41 CNY -2.90% Intraday chart for Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. +2.63% -25.56%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2022 3.97B 549M Sales 2023 4.43B 613M Capitalization 3.01B 416M
Net income 2022 42M 5.81M Net income 2023 59M 8.16M EV / Sales 2022 0.64 x
Net cash position 2022 221M 30.58M Net cash position 2023 40.46M 5.59M EV / Sales 2023 0.67 x
P/E ratio 2022
65.6 x
P/E ratio 2023
50.7 x
Employees 1,114
Yield 2022
0.69%
Yield 2023
0.7%
Free-Float 39.81%
More Fundamentals * Assessed data
Dynamic Chart
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023 CI
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Certain A Shares of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 25-JAN-2024. CI
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Sichuan Zhonghuisheng Traditional Chinese Medicine Material partnership (limited partnership) agreed to acquire 80% stake in Sichuan Hezong Traditional Chinese Medicine Pieces Co., Ltd. from Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. for CNY 6.7 million. CI
Sichuan Hezong Medicine Co., Ltd. Announces Cash Dividend on A Shares for 2022, Payable 22 May 2023 CI
Sichuan Hezong Medicine Co., Ltd. Approves Cash Dividend for 2022 CI
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hezong Medicine Easy-to-Buy Pharma to Apply For Up to 500 Million Yuan Bank Loan MT
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Li Yuemin agreed to acquire additional 58.02% stake in Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. from Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. for CNY 15.4 million. CI
Hezong Medicine Chairman Boosts Stake to 55% After 230 Million Yuan Deal MT
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
More news
1 day-2.90%
1 week+2.63%
Current month+2.63%
1 month-2.50%
3 months+15.21%
6 months-29.32%
Current year-25.56%
More quotes
1 week
22.96
Extreme 22.96
24.73
1 month
19.85
Extreme 19.85
24.73
Current year
17.83
Extreme 17.83
32.36
1 year
17.83
Extreme 17.83
42.15
3 years
17.83
Extreme 17.83
73.69
5 years
17.83
Extreme 17.83
150.00
10 years
17.83
Extreme 17.83
150.00
More quotes
Members of the board TitleAgeSince
Founder 54 07-04-27
Director/Board Member 53 16-06-05
Founder 56 07-04-27
More insiders
Date Price Change Volume
24-05-10 23.41 -2.90% 1,530,867
24-05-09 24.11 +2.03% 1,981,300
24-05-08 23.63 -1.13% 1,568,900
24-05-07 23.9 +1.92% 1,340,267

End-of-day quote Shenzhen S.E., May 09, 2024

More quotes
SICHUAN HZ-YEG MEDICAL Co Ltd is a China-based company mainly engaged in the pharmaceutical distribution industry. The Company mainly provides comprehensive medical circulation services in the out-of-hospital market. The Company's products cover western medicines, Chinese patent medicines, Chinese herbal medicines and Chinese medicinal materials, food and health food, medical equipment and non-medicinal products.
More about the company
  1. Stock Market
  2. Equities
  3. 300937 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW